

Original Research Article

A Study of Cancer Antigen-125 as a Diagnostic Marker in Tuberculous and Malignant Pleural Effusion

Abstract

Background: CA-125 was first known as a specific tumor marker of the ovary but gradually it was found that inflammation even without polymorphism (the early stage of pregnancy, menstrual cycle, PID, and endometriosis) causes this tumor marker to increase. Tuberculosis in various sites of body cause increase in serum antigen level. The aim of this study was to evaluate the diagnostic value of CA-125 and to determine the cut-off value, distinguishing tuberculous from malignant pleural effusion.

Methods: This is a prospective analytic case control study that was carried out on 90 patients above 18 years old and with a confirmed diagnosis of tuberculous, malignant and parapneumonic pleural effusion. Patients were classified equally into 3 groups: group I "Tuberculous": patients with a confirmed diagnosis of tuberculous pleural effusion, group II "Malignant": patients with a confirmed diagnosis of malignant pleural effusion and group III "Control": patients with a confirmed diagnosis of parapneumonic effusion.

Results: There was positive significant correlation between CA-125 in serum and pleural fluid in tuberculous effusion group (group I) and in malignant effusion group (group II).

Conclusions: Serum and pleural fluid CA-125 may be added to the diagnostic workup of pleural fluid for accurate diagnosis of pleural effusion cause.

Keywords: Cancer antigen-125, Tuberculous, Malignant pleural effusion

Comment [CHP1]: CA-125 was first known as a specific tumor marker of the ovary. However, it was gradually found that inflammation is even without polymorphism (the early stage of pregnancy, menstrual cycle, PID, and endometriosis) causes this tumor marker to increase.

Comment [CHP2]: ...sites of the body cause an increase...

Comment [CHP3]: This prospective analytic case control study was carried out on 90 patients above 18 years old with a confirmed diagnosis of tuberculous, malignant and parapneumonic pleural effusion.

Comment [CHP4]: ...an actual...

Comment [CHP5]: ...significant positive...

Comment [CHP6]: ...in the tuberculous...

Introduction:

Pleural effusion is the accumulation of liquid in the pleural cavity and is considered a result of a systemic or intrathoracic process. This pathological entity is a frequent problem in pulmonology and, though its incidence varies with clinical background, 90% of all pleural effusions are attributed to congestive heart failure, malignant processes, and pneumonia ^[1].

Comment [CHP7]: ...considered...

Comment [CHP8]: ...a clinical...

The main issues regarding pleural effusions are the differentiation of exudates and transudates and the accurate determination of effusion etiology (i.e., whether the pleural effusion is malignant or non-malignant). The differentiation of exudates and transudates requires the evaluation of various biochemical parameters and their comparison in pleural fluid and serum. When differentiating transudates from exudates using classical Light's criteria, it is helpful to recognize the pathogenic mechanism resulting in the pleural effusion. Recognizing the correct pathogenic mechanism is also useful for the purpose of differential diagnosis ^[2].

CA-125 is a 200 KD glycoprotein, which exists on the surface of ovarian, and some inflammatory and non-inflammatory cells. Proliferation of these cells causes this antigen to be released in serum.

Comment [CHP9]: The proliferation...

CA125 was first known as a specific tumor marker of the ovary but gradually it was found that inflammation even without polymorphism (the early stage of pregnancy, menstrual cycle, PID, and endometriosis) causes this tumor marker to increase. Later it was revealed that tuberculosis in various sites of body cause increase in serum Antigen level ^[3-5]. Increased serum CA-125 level in both malignancy and tuberculosis, caused some limitations in the use of this tumor marker in a way that the role of CA-125 was decreased as an acute phase reactor and a factor for observing the response to treatments ^[6, 7].

Comment [CHP10]: ...of the body cause an increase...

Comment [CHP11]: ...levels...

The aim of this study was to evaluate the diagnostic value of CA-125 and to determine the cut-off value, distinguishing tuberculous from malignant pleural effusion.

Comment [CHP12]: This study aimed to evaluate the diagnostic value of CA-125 and determine the cut-off value, distinguishing tuberculous from malignant pleural effusion.

Patients and Methods:

This is a prospective **analytic case control** study that was carried out on 90 patients above 18 years old with a confirmed diagnosis of tuberculous, **malignant and parapneumonic pleural effusion in Chest Department**, Tanta University Hospitals and Tanta Chest Hospital.

Comment [CHP13]: ...analytic case-control...

An informed written consent was obtained from all patients. The study was done after approval from the Ethical Committee Tanta University Hospitals.

Comment [CHP14]: ...malignant, and parapneumonic pleural effusion in the Chest Department,...

Comment [CHP15]: Informed...

Exclusion criteria were patients with hepatic cirrhosis, heart failure, or any other non-infectious diseases, female patients with endometriosis and pregnancy and age less than 18 years.

Patients were classified equally into 3 groups: group I "Tuberculous": patients with a confirmed diagnosis of tuberculous pleural effusion, group II "Malignant": patients with a confirmed diagnosis of malignant pleural effusion and group III " Control": patients with a confirmed diagnosis of parapneumonic effusion.

All patients were subjected to cancer antigen-125 "CA-125" measured in both serum and pleural fluid using **ELISA kit**.

Comment [CHP16]: ...an ELISA kit.

CA 125 ELISA

The CA-125 **ELISA-kit is a solid phase** enzyme-linked immunosorbent assay (ELISA) based on the sandwich principle. The microtiter wells were coated with a monoclonal [mouse] antibody directed towards a unique antigenic site of the CA-125 molecule. An **aliquot of patient sample** containing endogenous CA-125 was incubated in the coated well with enzyme conjugate, which is a monoclonal **anti CA-125** antibody conjugated with horseradish peroxidase.

Comment [CHP17]: ELISA-kit is a solid-phase...

Comment [CHP18]: ...aliquot of the patient sample...

Comment [CHP19]: ...anti-CA-125...

Statistical analysis

Statistical analysis was done by SPSS v26 (IBM Inc., Chicago, IL, USA). Quantitative variables were presented as mean and standard deviation (SD) and compared between the two groups utilizing ANOVA (F) test. Qualitative variables were presented as frequency and percentage (%) and were analysed utilizing the Chi-square test or Fisher's exact test when appropriate. Linear Correlation and

ROC-curve (receiver operating characteristic curve analysis) were utilised. A two tailed P value <

Comment [CHP20]: A two-tailed...

0.05 was considered statistically significant

Results:

Age was significantly higher in group II when compared to group III (P3 = 0.009) with no statistically significant difference between groups I and II (P1 = 0.092) or groups I and III (P2 = 0.343). Sex was insignificantly different between the three studied groups. Table 1

Table 1: Age and sex in the three studied groups

		Group I	Group II	Group III	P. value		
Age		54.60 ± 14.79	60.80 ± 15.84	51.13 ± 11.17	0.031*	P1	
						P2	0.092
						P3	0.343
Sex	Male (%)	22 (73.3%)	16 (53.3%)	20 (66.7%)	0.257	P1	
	Female (%)	8 (26.7%)	14 (46.7%)	10 (33.3%)		P2	0.107
						P3	0.573
						0.292	

Data are presented as mean ± SD or frequency (%). P1: Group I & Group II; P2: Group I & Group III; P3: Group II & Group III, *: statistically significant as P value ≤ 0.05

X ray findings were significantly different in the three studied groups (P value= 0.001). TLC and CRP were significantly higher in group III when compared to groups I and II (P2=0.024, P3=0.011, P2 = 0.001, P3 = 0.001 respectively) with no statistically significant difference between groups I and II. ESR was significantly higher in group I when compared to group II and III (P1=0.001) and (P2=0.001) respectively, with no statistically significant difference between groups II and III. Table 2

Comment [CHP21]: X-ray...

Comment [CHP22]: ...groups...

Table 2: X ray and routine laboratory findings in the three studied groups

		Group I (N=30)	Group II (N=30)	Group III (N=30)	P-value
X ray findings	Unilateral obliteration of costophrenic angle rising to axilla	9 (30%)	9 (30%)	19 (63.3%)	0.001*
	Unilateral upper lobe infiltration + unilateral obliteration of costophrenic angle rising to axilla	17 (56.7%)	0 (0%)	0 (0%)	

Comment [CHP23]: X-ray...

Comment [CHP24]: X-ray findings

	Unilateral upper lobe cavitory lesion + unilateral obliteration of costophrenic angle rising to axilla	4 (13.3%)	0 (0)	0 (0%)	
	Unilateral well defined opacity + unilateral obliteration of costophrenic angle rising to axilla	0 (0%)	10 (33.3%)	0 (0%)	
	Bilateral multiple opacities + unilateral obliteration of costophrenic angle rising to axilla	0 (0%)	11 (36.7%)	0 (0%)	
	Unilateral consolidation with air bronchogram + unilateral obliteration of costophrenic angle rising to axilla	0 (0%)	0 (0%)	11 (36.7%)	
Laboratory findings	TLC (mm³)	8386.67 ± 2081.73	8153.33 ± 3656.05	10160.00 ± 3020.57	0.021* P1= 0.763 P2= 0.024* P3= 0.011*
	ESR (mm/h)	108.67 ± 21.29	17.07 ± 18.23	42.33 ± 17.99	0.001* P1= 0.001* P2= 0.001* P3= 0.372*
	CRP (mg/L)	15.33 ± 11.86	11.67 ± 14.35	112.93 ± 70.81	0.001* P1= 0.738 P2= 0.001* P3= 0.001*

Data are presented as mean ± SD or frequency (%). P1: Group I & Group II; P2: Group I & Group III; P3: Group II & Group III, TLC: total leucocytic count, ESR: Erythrocyte Sedimentation Rate, CRP: C-reactive protein, *: statistically significant as P value ≤ 0.05

Positive tuberculin test and turbid yellow appearance were significantly higher in group I compared to group II and group III (P value <0.05). Cloudy appearance, growth of culture and sensitivity of pleural fluid were significantly higher in group III compared to group I and group II. (P value= 0.001). Bloody turbid appearance, serum CA-125 and pleural CA-125 were significantly higher in group II compared to group I and group III (P value <0.05). Serum CA-125 and pleural CA-125 were significantly higher in group I when compared to group III (P2 <0.05). Table 3

Comment [CHP25]: ...well-defined...

Comment [CHP26]: ...group II and III...

Comment [CHP27]: Cloudy appearance, culture growth, and pleural fluid sensitivity higher in group III than in group I and group II.

Comment [CHP28]: ...group I compared to...

Table 3: Comparison between the three studied groups as regard to Tuberculin test, gross appearance, culture and sensitivity of pleural fluid, serum levels of CA125 and Pleural CA-125 U/ml

Comment [CHP29]: ...groups with regard to the Tuberculin...

		Group I	Group II	Group III	P-value
Tuberculin test	+ve	18 (60.0%)	10 (33.3%)	8 (26.7%)	0.020*
	-ve	12 (40.0%)	20 (66.7%)	22 (73.3%)	
Gross appearance	Cloudy	0 (0%)	0 (0%)	6 (20.0%)	0.001*
	Turbid yellow	22 (73.3%)	8 (26.7%)	18 (60.0%)	
	Bloody turbid	8 (26.7%)	22 (73.3%)	6 (20.0%)	
Culture and sensitivity of pleural fluid	Growth	0 (0%)	0 (0%)	26 (86.7%)	0.001*
	No growth	30 (100%)	30 (100%)	4 (13.3%)	
Serum CA-125 U/ml		120.07 ± 112.77	363.67 ± 221.40	29.40 ± 19.32	0.001* P1= 0.001* P2= 0.017* P3= 0.001*
Pleural CA-125 U/ml		138.83 ± 149.43	780.87 ± 427.27	44.83 ± 29.02	0.001* P1= 0.001* P2= 0.034* P3= 0.001*

Data are presented as mean ± SD or frequency (%). P1: Group I & Group II; P2: Group I & Group III; P3: Group II & Group III, CA: cancer antigen, *: statistically significant as P value ≤ 0.05

Specific gravity and pleural fluid protein / serum protein ratio were insignificantly different in the three studied groups. PH was significantly lower in group I than group II (P1=0.001), and in group III than groups I and II (P <0.05). Protein and LDH were significantly higher in groups II and III than group I (P <0.05), with no statistically significant difference between groups II and III. Glucose was significantly higher in groups I and II than group III (P <0.05), with no statistically significant difference between groups I and II. Pleural fluid LDH / serum LDH ratio was significantly higher in group II than groups I and III (P1 <0.05), and in group III than group I (P2=0.001). ADA was significantly higher in group I than groups II and III (P <0.05), with no statistically significant difference between group II and III. Table 4

Comment [CHP30]: ...than in group...

Comment [CHP31]: ...than in groups...

Comment [CHP32]: ...than in group...

Comment [CHP33]: The pleural...

Comment [CHP34]: ...than in groups...

Comment [CHP35]: ...than in group...

Comment [CHP36]: ...between groups...

Table 4: Thoracentesis parameters in the three studied groups


		Mean ± S. D	P. value		
Specific gravity	Group I	1026.80 ± 7.68	0.909	P1	0.706
	Group II	1027.53 ± 7.18		P2	0.708

	Group III	1027.53 ± 7.64		P3	0.999
PH	Group I	7.17 ± 0.06	0.001*	P1	0.001*
	Group II	7.39 ± 0.06		P2	0.001*
	Group III	7.02 ± 0.14		P3	0.001*
	Group I	4.06 ± 0.63		P1	0.022*
Protein (mg/dl)	Group II	4.62 ± 1.08	0.018*	P2	0.009*
	Group III	4.70 ± 1.02		P3	0.753
	Group I	44.00 ± 10.09		0.001*	P1
Glucose (mg/dl)	Group II	40.80 ± 6.83	P2		0.001*
	Group III	27.27 ± 6.92	P3		0.001*
	Group I	510.07 ± 100.11	0.001*	P1	0.001*
LDH (U/L)	Group II	1251.13 ± 548.35		P2	0.001*
	Group III	1475.40 ± 639.01		P3	0.080
	Group I	0.71 ± 0.09	0.910	P1	0.776
Pleural Ptn./S. Ptn.	Group II	0.70 ± 0.09		P2	0.670
	Group III	0.70 ± 0.09		P3	0.887
	Group I	0.95 ± 0.21	0.001*	P1	0.001*
Pleural LDH/S. LDH	Group II	1.91 ± 0.49		P2	0.001*
	Group III	1.60 ± 0.57		P3	0.009*
	Group I	60.80 ± 9.66	0.001*	P1	0.001*
ADA (U/L)	Group II	17.37 ± 9.77		P2	0.001*
	Group III	21.57 ± 13.91		P3	0.1543

Data are presented as mean ± SD or frequency (%). P1: Group I & Group II; P2: Group I & Group III; P3: Group II & Group III, LDH: lactate dehydrogenase; Ptn: protein; S: serum, ADA: adenosine deaminase, *: statistically significant as P value ≤ 0.05

There was positive significant correlation between CA-125 in serum and pleural fluid in tuberculous effusion group (group I) and in malignant effusion group (group II). Figure 1

Comment [CHP37]: There was significant positive correlation between CA-125 in serum and pleural fluid in the tuberculous effusion group (group I) en in the malignant...



(A) (B)
Figure 1: Positive significant correlation between CA-125 in serum and pleural fluid in (A) tuberculous effusion group (group I) and (B) malignant effusion group (group II)

Regarding (group I & group II) and group III, CA125 in pleural fluid, at the cut off value of 45 the sensitivity was 93% and the specificity was 83%. While CA125 in serum, at the cut off value of 40 the sensitivity was 82% and the specificity was 77%. Regarding group I & group II, CA125 in

Comment [CHP38]: ...the cut-off...

Comment [CHP39]: ...the cut-off value...

pleural fluid, at the cut off value of 110 the sensitivity was 90% and the specificity was 80%. While CA125 in serum, at the cut off value of 100 the sensitivity was 73% and the specificity was 67%.

Comment [CHP40]: ...cut-off value...

Comment [CHP41]: ...at the cut-off value...

Figure 2




Figure 2: Roc curve show sensitivity and specificity of CA125 in pleural fluid and serum between cases of (A)[Group I & Group II] and Group III and (B) [Group I & Group II]

Discussion

In our work, adenosine deaminase (ADA) (U/L) was significantly higher in Group I when compared to Group II and III ($P_1 = 0.001$) and ($P_2 = 0.001$) respectively, with no statistically significant difference between Group II and III ($P_3 = 0.1543$).

In the same way, in Lee et al. ^[10], the median values of pleural fluid ADA levels in patients with TPE and PPE were 82 and 50 U/L, respectively, and were significantly different between the two groups ($P < 0.001$).

In our study, serum levels of CA-125 (U/ml) was significantly higher in Group II when compared to Groups I and III ($P_1=0.001$) and ($P_3 = 0.001$) respectively, and in Group I when compared to Group III ($P_2=0.017$).

Comment [CHP42]: ...were significantly...

In contrast, Zhai et al. ^[11] enrolled 174 patients, including 67 malignant pleural effusion (MPE) and 107 benign pleural effusion (BPE) found that, the concentration of serum CA-125, in MPE patients was not significantly higher than those in BPE patients.

Comment [CHP43]: ...that the concentration...

Comment [CHP44]: ...in MPE patients,...

Similarly, Mohammad et al. ^[12] enrolled 80 patients were classified into 3 groups: group I: active pulmonary tuberculosis, group II: pneumonia, group III: apparently healthy subjects as control group. They reported that, there was statistically significant difference among the three studied groups according to serum level of CA 125($P < 0.05$). The serum level of CA125 was significantly higher in group I in their work.

Comment [CHP45]: ...enrolled 80 patients and were...

Comment [CHP46]: ...as a control group.

Comment [CHP47]: They reported that there was a statistically significant difference among the three groups according to the serum level...

In our study regarding CA-125 between cases of (Group I & Group II) and Group III in serum at the cut off value of 40; the sensitivity, specificity, positive and negative predictive values and diagnostic accuracy were 82%, 77%, 88%, 68%, 80%.

While regarding CA-125 between cases of (Group I & Group II) in serum at the cut off value of 100; the sensitivity, specificity, positive and negative predictive values and diagnostic accuracy were 73%, 67%, 69%, 71%, 70% respectively.

According to sensitivity of CA-125, in Mohammad et al. ^[12], at a CA-125 serum level of 21.05 U/ml as a cut-off value, CA-125 had sensitivity, specificity, positive and negative predictive values and diagnostic accuracy of 82.5%, 72.5%, 77.3%, 83.3% and 80.0% respectively.

Our data showed that pleural fluid levels of CA-125 (U/ml) was significantly higher in Group II when compared to Groups I and III ($P_1=0.001$) and ($P_3 = 0.001$) respectively, and in Group I when compared to Group III ($P_2=0.034$).

Also, in our study regarding CA-125 between cases of (Group I & Group II) and Group III in pleural fluid at the cut off value of 45; the sensitivity, specificity, positive and negative predictive values and diagnostic accuracy were 93%, 83%, 92%, 86%, 90%.

While regarding CA125 between cases of (Group I & Group II) in pleural fluid at the cut off value of 110; the sensitivity, specificity, positive and negative predictive values and diagnostic accuracy were 90%, 80%, 82%, 89%, 85% respectively.

Similarly, in Santotoribio et al. ^[13], of total, 81 patients had benign pleural effusion (BPE) and 52 had malignant pleural effusion (MPE). The pleural fluid concentrations of CA125 were significantly higher in MPE patients than in BPE patients with P-value (0.037).

Our data showed that correlations between CA-125 in serum and pleural fluid levels was highly positive significant P=0.001 in malignant effusion group (group II) and in tuberculous effusion group (group I).

The studies addressing the level of tumor markers in serum and pleural fluid were reviewed, but only a few described P/S ratio. In Gu et al. ^[14] study, they found that the Pleural fluid/Serum ratio of CA-125 was lower in TPE than in MPE.

Limitations: this study, however, has several limitations. First, we obtained single center participants in our study. In addition, the sensitivity and specificity of CA-125 was not assessed in combination with other biomarkers.

Conclusions:

Serum and pleural fluid CA-125 levels may be used for differentiation between TB and malignancy-induced effusions. Also, CA-125 may be added to the diagnostic workup of pleural fluid for accurate diagnosis of malignant pleural effusion.

References:

1. Trapé J, Sant F, Franquesa J, Montesinos J, Arnau A, Sala M, et al. Evaluation of two strategies for the interpretation of tumour markers in pleural effusions. *Respir Res.* 2017;18:103.
2. Ferreiro L, Toubes ME, Valdés L. [Contribution of pleural fluid analysis to the diagnosis of pleural effusion]. *Med Clin (Barc).* 2015;145:171-7.
3. Nebhani M, Boumzgou K, Brams S, Laghzaoui M, El Attar H, Bouhya S, et al. [Pelvic tuberculosis mimicking bilateral ovarian tumor. A case report]. *J Gynecol Obstet Biol Reprod (Paris).* 2004;33:145-7.
4. Mas MR, Cömert B, Sağlamkaya U, Yamanel L, Kuzhan O, Ateşkan U, et al. CA-125; a new marker for diagnosis and follow-up of patients with tuberculous peritonitis. *Dig Liver Dis.* 2000;32:595-7.
5. Strauss RM, Townsend R, Green ST, Prakasam SF, Read RC, Mohsen AH. Peritoneal tuberculosis and elevated serum CA 125 levels: recognizing the association is important. *J Infect.* 2001;43:256-7.
6. Yilmaz A, Ece F, Bayramgürler B, Akkaya E, Baran R. The value of Ca 125 in the evaluation of tuberculosis activity. *Respir Med.* 2001;95:666-9.
7. Jacobs EL, Haskell CM. Clinical use of tumor markers in oncology. *Curr Probl Cancer.* 1991;15:299-360.
8. Feller-Kopman D, Berkowitz D, Boiselle P, Ernst A. Large-volume thoracentesis and the risk of reexpansion pulmonary edema. *Ann Thorac Surg.* 2007;84:1656-61.
9. Barnes TW, Morgenthaler TI, Olson EJ, Hesley GK, Decker PA, Ryu JH. Sonographically guided thoracentesis and rate of pneumothorax. *J Clin Ultrasound.* 2005;33:442-6.
10. Lee J, Yoo SS, Lee SY, Cha SI, Park JY, Kim CH. Pleural fluid adenosine deaminase/serum C-reactive protein ratio for the differentiation of tuberculous and parapneumonic effusions with neutrophilic predominance and high adenosine deaminase levels. *Infection.* 2017;45:59-65.

11. Zhai K, Wang W, Wang Y, Liu JY, Zhou Q, Shi HZ. Diagnostic accuracy of tumor markers for malignant pleural effusion: a derivation and validation study. *J Thorac Dis.* 2017;9:5220-9.
12. Mohammad OI, Okab AA, El Behisy MM, Sudhom FGT. Value of CA-125 in diagnosis and assessment of severity of active pulmonary tuberculosis. *Egypt J Chest Dis Tuberc.* 2016;65:205-9.
13. Santotoribio JD, Del Valle-Vazquez L, García-de la Torre A, Del Castillo-Otero D, Lopez-Saez JB, Sanchez Del Pino MJ. The diagnostic value of pleural fluid homocysteine in malignant pleural effusion. *PLoS One.* 2019;14:0222616.
14. Gu Y, Zhai K, Shi HZ. Clinical value of tumor markers for determining cause of pleural effusion. *Chin Med J (Engl).* 2016;129:253-8.